Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
Venrock Healthcare Capital Partners (WA:CPAP) III, L.P., a significant stakeholder in Oruka Therapeutics, Inc. (NASDAQ:ORKA), recently acquired a substantial amount of the company’s common stock. According to a recent SEC filing, Venrock made a series of purchases totaling $1,407,367. The transactions, which occurred between February 10 and February 14, 2025, involved buying shares at prices ranging from $10.90 to $11.86 per share. Since these purchases, the stock has declined to $9.56, trading near its 52-week low of $9.53, according to InvestingPro data.
The acquisitions added a total of 128,882 shares to Venrock’s holdings, increasing their stake in Oruka Therapeutics. The purchases were made indirectly through various funds associated with Venrock, as noted in the filing. This move reflects Venrock’s continued interest in Oruka Therapeutics, a company involved in pharmaceutical preparations, with its headquarters in Menlo Park, California. With a market capitalization of $368.5 million, analysts maintain a strong buy consensus with price targets ranging from $20 to $49 per share. InvestingPro subscribers can access 8 additional technical indicators and valuation metrics for ORKA.
These transactions are part of Venrock’s ongoing investment strategy and demonstrate their confidence in Oruka Therapeutics’ potential in the pharmaceutical sector, despite InvestingPro data showing the stock has declined 67% over the past six months.
In other recent news, Oruka Therapeutics has entered into an exclusive licensing agreement with Paragon Therapeutics. This deal grants Oruka the worldwide rights to develop, manufacture, and commercialize antibodies targeting IL-17A/F and IL-23, with potential milestone payments to Paragon reaching up to $22 million. Oruka will also pay royalties on sales of these antibody products, with provisions for reduction if no effective Paragon patents exist during the royalty term. Additionally, Oruka has started dosing volunteers in the Phase 1 study of its leading drug candidate, ORKA-001, marking a significant milestone as it transitions its first product into clinical trials earlier than expected. H.C. Wainwright has maintained a Buy rating for Oruka, with a price target of $45 per share, reflecting confidence in the company’s recent developments and the potential of ORKA-001. The Phase 1 trial is a double-blind, placebo-controlled study involving 24 healthy volunteers and is expected to provide interim data in the second half of 2025. If successful, Oruka plans a proof-of-concept study for ORKA-001 targeting moderate-to-severe psoriasis. These developments highlight Oruka’s strategic efforts to strengthen its portfolio and advance its clinical pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.